Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News

Pharma News

WuXi Bio answers the growing demand for ADC manufacturing
WuXi Bio answers the growing demand for ADC manufacturing
Antibody-drug conjugates are rushing to the fore.
Incyte's ruxolitinib cream hits goal in vitiligo phase 3 trials, teeing up regulatory submissions
Incyte's ruxolitinib cream hits goal in vitiligo phase 3 trials, teeing up regulatory submissions
Phase 3 trials of Incyte’s ruxolitinib cream in patients with vitiligo have met their primary endpoints.
InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
BEIJING--(BUSINESS WIRE) -- InnoCare (HKEX.
Neurodon Announces Initiation of Investigational New Drug (IND)-Enabling Studies for NDC-0009, a Novel Small Molecule for the Treatment of Type 1 Diabetes (T1D)
Neurodon Announces Initiation of Investigational New Drug (IND)-Enabling Studies for NDC-0009, a Novel Small Molecule for the Treatment of Type 1 Diabetes (T1D)
CROWN POINT, IN, USA I May 17, 2021 I Neurodon Corporation today announced the initiation of essential studies necessary to enable preparation of an Investigational New Drug (IND) application ...
New Technology Makes Tumor Eliminate Itself
New Technology Makes Tumor Eliminate Itself
A new technology developed by UZH researchers enables the body to produce therapeutic agents on demand at the exact location where they are needed.
Vitamin B3 as a possible treatment for glaucoma
Vitamin B3 as a possible treatment for glaucoma
Glaucoma involves a high risk of losing sight.
U.S. administers 273.5 mln doses of COVID-19 vaccines - CDC
U.S. administers 273.5 mln doses of COVID-19 vaccines - CDC
The United States has administered 273,545,207 doses of COVID-19 vaccines in the country as of Sunday morning and distributed 344,503,495 doses, the U.
Biogen’s inherited eye disease gene therapy misses primary endpoint
Biogen’s inherited eye disease gene therapy misses primary endpoint
A gene therapy developed by Biogen for the rare inherited eye disease X-linked retinitis pigmentosa (XLRP) has failed to meet the primary endpoint in a Phase II/III study.
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results
Sanofi, GSK’s COVID-19 vaccine achieves positive Phase II results
Sanofi and GlaxoSmithKline (GSK) have reported that their COVID-19 vaccine generates strong immune responses across all adult age groups.
Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal
Lilly buys into MiNA’s protein-boosting RNA tech in $1.25bn deal
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to ge...
Pfizer says 'good reason' to believe in success of anti-viral drug
Pfizer says 'good reason' to believe in success of anti-viral drug
ATHENS (Reuters) - The chief executive of Pfizer Inc said on Friday he had “very good reason” to believe in the success of an oral COVID-19 antiviral therapy by the drugmaker now in an ear...
Drug R&D innovation reshaping manufacturing and the CDMO sector
Drug R&D innovation reshaping manufacturing and the CDMO sector
Our virtual CPHI Discover event (17th-28th May) is just around the corner, full to the brim with three main content tracks.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand